Top Markets
Coin of the day
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.

Millendo Therapeutics, Inc.

MLND
Rank in Stocks #40617
Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to... Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause. This enterprise maintains its primary operational base in Ann Arbor, Michigan.
Share Price
$1.06
Last synced: 2021-06-25
Market Cap
$110.93K
Change (1 day)
-5.36%
Change (1 year)
0.00%
Country
US
Trade Millendo Therapeutics, Inc. (MLND)

Category

P/S ratio for Millendo Therapeutics, Inc. (MLND)
P/S ratio as of 2026 TTM: 0
According to Millendo Therapeutics, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Millendo Therapeutics, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE